Date:- 3 May, 2018
Tag:- IMMUNOSCORE® in Colon Cancer

HalioDx SAS, an immuno-oncology diagnostic company, today announced that Immunoscore® Colon CE-IVD workflow is now compatible with Philips IntelliSite Pathology Solution, a high-throughput digital pathology solution for primary diagnostics, to help improve accuracy and efficiency for colon cancer diagnosis. The collaboration aims to provide a clinically validated and regulatory compliant Immunoscore® workflow leveraging both companies’ technologies.

Immunoscore® Colon is a unique diagnostic assay that predicts the risk of recurrence of patients with localized colon cancer, to help guide treatment strategies. Available as a CE-IVD (in vitro diagnostic) solution in Europe since January 2017, Immunoscore® Colon quantifies T-cells which infiltrate both the core of the tumor and its invasive margin. The assay is used to help oncologists decide on critical therapeutic options in stages II and III colon cancers.

Immunoscore® Colon combines tissue diagnostic and advanced image analysis technologies. It is the very first IVD assay of the HalioDx pipeline, leveraging digital pathology technology to enhance clinical utility and standardization.

“We are delighted to collaborate with Philips as both companies develop complementary solutions with ultimately the same goal of delivering precision oncology solutions that make a difference in daily practices of pathology laboratories and patients life,said Vincent FERT, CEO of HalioDx.In addition, we believe that Philips’ technology is particularly suited to our Immunoscore® as the Philips IntelliSite Pathology Solution is designed to meet the needs of high volume labs.

Digital technology has accelerated innovation across many healthcare applications and is now revolutionizing pathology services,says Dirk Vossen, Business Development Computational Pathology at Philips Digital Pathology Solutions .“Combining the Philips IntelliSite Pathology Solution with HalioDx’s Immunoscore® Colon test augments diagnostic assays with computational technologies to provide pathologists with a unique assessment of the immune contexture of colon cancer. Gaining this advanced insight will help guide treatment decisions and ultimately help improve patient care.

Immunoscore® Colon was developed by Dr. Jérôme Galon. The clinical value was validated in a SITC International study including more than 3500 patients.



Related Files